Vanguard Group Inc. Has $169.54 Million Position in GRAIL, Inc. $GRAL

Vanguard Group Inc. increased its position in shares of GRAIL, Inc. (NASDAQ:GRAL) by 9.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,980,783 shares of the company’s stock after purchasing an additional 163,790 shares during the quarter. Vanguard Group Inc. owned about 0.05% of GRAIL worth $169,535,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. N.E.W. Advisory Services LLC acquired a new stake in GRAIL during the 4th quarter worth approximately $26,000. Comerica Bank raised its holdings in GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock valued at $27,000 after acquiring an additional 173 shares in the last quarter. Rossby Financial LCC acquired a new position in GRAIL in the 3rd quarter valued at $62,000. Atlantic Union Bankshares Corp acquired a new position in GRAIL in the 3rd quarter valued at $64,000. Finally, Whittier Trust Co. raised its holdings in GRAIL by 19.3% in the 4th quarter. Whittier Trust Co. now owns 1,114 shares of the company’s stock valued at $95,000 after acquiring an additional 180 shares in the last quarter.

Insider Activity

In other news, CFO Aaron Freidin sold 45,806 shares of GRAIL stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total value of $2,286,635.52. Following the transaction, the chief financial officer owned 260,669 shares in the company, valued at approximately $13,012,596.48. This trade represents a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Robert P. Ragusa sold 123,502 shares of GRAIL stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $6,165,219.84. Following the completion of the transaction, the chief executive officer owned 518,582 shares in the company, valued at approximately $25,887,613.44. The trade was a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 310,267 shares of company stock worth $15,485,396. Insiders own 1.83% of the company’s stock.

GRAIL Price Performance

Shares of NASDAQ GRAL opened at $61.64 on Monday. GRAIL, Inc. has a fifty-two week low of $29.95 and a fifty-two week high of $118.84. The business has a fifty day moving average price of $51.05 and a two-hundred day moving average price of $78.44. The stock has a market capitalization of $2.65 billion, a PE ratio of -5.94 and a beta of 3.03.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.76) by $0.47. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The company had revenue of $40.79 million for the quarter, compared to analyst estimates of $39.16 million. On average, equities analysts expect that GRAIL, Inc. will post -11.09 EPS for the current year.

Wall Street Analyst Weigh In

GRAL has been the subject of several analyst reports. Morgan Stanley dropped their price objective on GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Guggenheim dropped their price objective on GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a report on Monday, March 30th. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a report on Saturday. TD Cowen lifted their price objective on GRAIL from $65.00 to $69.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Canaccord Genuity Group dropped their price objective on GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a report on Friday, February 20th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $67.88.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.